OS Therapies closes $4.2M warrant exercise inducement; extends cash runway to 2026

OS Therapies Inc

Raised $4.2M gross from exercise of 3.8M existing warrants at $1.12/share; issued new warrants at $3.00/share.
Cash runway extended through 2026, beyond Sept 30, 2026 PRV sunset date for rare pediatric diseases.
Proceeds to support OST-HER2 regulatory efforts for osteosarcoma, advance OS Animal Health, close OST-504 prostate cancer study, and initiate AI-driven ADC modeling.
CEO Paul Romness highlighted End of Phase 2 meeting with FDA and Scientific Advice Meetings in UK/Europe.
New warrants exercisable for 5 years at $3.00/share; forced exercise if stock hits 300% of exercise price for 20 consecutive trading days.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.